The pharmaceutical industry for 60 years failed to produce a safe RSV vaccine, following a botched attempt in the 1960s. We've all lived with this virus, and most babies afflicted with it are treated easily with a nebulizer. Yet suddenly, the Food and Drug Administration and Centers for Disease Control have approved three different vaccines — all for different demographics — at warp speed (ahem), despite serious safety concerns.

Now, pharmacies are carelessly mixing up each type of vaccine and even giving children the adult version because, when it comes to vaccines, "it's all good."

The FDA last year approved RSV shots for three different groups: GSK's Arexvy and Pfizer's Abrysvo for seniors over 60; Pfizer's Abrysvo variant for pregnant women; and AstraZeneca's Nirsevimab, a monoclonal antibody, for newborn babies.